IPSEN (OTCMKTS:IPSEY) Stock Short Interest Report for October

IPSEN (OTCMKTS:IPSEY) was the recipient of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 606 shares, a decrease of 57.5% from the September 30th total of 1,426 shares. Based on an average daily volume of 5,390 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Analyst Ratings Changes

A number of brokerages recently commented on IPSEY. Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

IPSEN Stock Performance

Shares of IPSEN stock traded up $0.11 on Friday, hitting $44.46. The company had a trading volume of 458 shares, compared to its average volume of 2,775. The stock has a 50 day moving average of $43.96 and a 200-day moving average of $45.20. IPSEN has a 1 year low of $34.34 and a 1 year high of $51.10.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.